Abstract: The present invention provides a rabies virus monoclonal antibody 2F2 and universal rabies virus antibody rapid detection test paper and belongs to the technical field of biological detection. An amino acid sequence of the monoclonal antibody 2F2 is shown as SEQ ID No. 1. The monoclonal antibody 2F2 provided by the present invention specifically binds to rabies virus G proteins, and preparation of the monoclonal antibody 2F2 into test paper has the advantages of rapidity, accuracy, sensitivity, specificity and low cost.

Abstract: Provided herein are devices and systems for depositing a material or manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. Further provided are methods of using the devices and systems, as well as methods of manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. In certain embodiments, the device includes a material supply system configured to melt an pressurized a material, a pressure sensor configured to detect a pressure of the material within the device, and a control switch comprising a sealing needle operable in an open position and closed position. The sealing needle extends through a feed channel containing the material and includes a taper end, wherein the tapered end of the sealing needle engages a tapered inner surface of a nozzle to inhibit flow of the material through the nozzle when the sealing needle is in the closed position.

Abstract: Provided herein are devices and systems for depositing a material or manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. Further provided are methods of using the devices and systems, as well as methods of manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. In certain embodiments, the device includes a material supply system configured to melt an pressurized a material, a pressure sensor configured to detect a pressure of the material within the device, and a control switch comprising a sealing needle operable in an open position and closed position. The sealing needle extends through a feed channel containing the material and includes a taper end, wherein the tapered end of the sealing needle engages a tapered inner surface of a nozzle to inhibit flow of the material through the nozzle when the sealing needle is in the closed position.

Abstract: A high throughput, efficient, and simplified unloading and packaging systems and methods for large-scale production of pharmaceutical units (104) using additive manufacturing. The systems and methods may unload, inspect, package, and trace pharmaceutical units, produced by an additive manufacturing system (900), that are not damaged or deformed. The unloading and packaging system can include one or more unloading and packaging devices (100). The unloading and packaging device can include a modular configuration having modules. Individual modules to be arranged in any relative order, at any location, and with any number in the unloading and packaging device. The flexibility of the modular configuration allows one or more modules to be removed or added at any given time due to, e.g., expansion, downsizing, module repair, module upgrades, etc. High throughput can be achieved by operating unloading and packaging devices independently.

Abstract: The present disclosure relates generally to manufacturing pharmaceutical products using additive manufacturing technology.

Abstract: The disclosure provides an electricity generating insert for a piece of footwear, the insert can be removably placed in the heel portion, e.g. under the insole. The insert comprises a multilayer piezoelectric stack that alternatively flexes under the compression-decompression that occurs during locomotion, which flexing causes friction in the stack to generate electricity capable of charging electronic devices and the like, e.g. via a port on the footwear.

Abstract: A 3D printing device (100), comprising a melt extrusion module (102), a printing module (103), and a platform module (104). The melt extrusion module (102) comprises a processing chamber (121) consisting of a feed inlet (124) and a discharge outlet (125), as well as an extrusion means (122) and a heating means (123) disposed at the processing chamber; the melt extrusion module (102) is configured to receive an initial material from the feed inlet (124) of the processing chamber (121), and heat and extrude the initial material to convert the initial material into a molten body, which is extruded out of the discharge outlet (125) of the processing chamber (121). The printing module (103) is communicated with the discharge outlet (125) of the processing chamber (121) and is provided with a nozzle (131); the printing module (103) is configured to receive the molten body extruded from the discharge outlet (125) of the processing chamber (121) and guide the molten body to be extruded out of the nozzle (131).

Abstract: The present disclosure relates generally to manufacturing pharmaceutical products using additive manufacturing technology.

Abstract: Provided are a glycosyltransferase UGT76G1 mutant, an isolated polynucleotide, a carrier, a production method, and a composition and a kit for the glycosylation of substrates. Further provided are a method for increasing the catalytic activity of the glycosyltransferase UGT76G1 mutant, and a method for promoting the glycosylation of flavone compounds and the use thereof. The glycosyltransferase UGT76G1 mutant is subjected to mutations at positions corresponding to positions 87, 199, 204 or 379 of SEQ ID NO: 1, and significantly improves the transformation activity of substrates of the flavone compounds.

Abstract: Provided are a mutant glycosyltransferase UGT76G1 and a use therefor, the catalytic activity, the substrate selectivity, and/or the substrate specificity of the mutant glycosyltransferase UGT76G1 having been changed. Mutation at specific points can promote the catalytic activity for 1,3-glycosylation of a substrate containing 1,2-diglucosyl (sophorosyl), and weaken the catalytic activity thereof to perform 1,3-glycosylation on a glucose monosaccharide substrate base. Also provided are mutations that weaken the catalytic activity of glycosyltransferase UGT76G1, able to increase accumulation of a specific stevioside intermediate.

Abstract: The present disclosure relates generally to manufacturing pharmaceutical products using additive manufacturing technology.

Abstract: The present disclosure relates generally to manufacturing pharmaceutical products using additive manufacturing technology.

Abstract: The present disclosure relates generally to manufacturing pharmaceutical products using additive manufacturing technology.

Abstract: A 3D printing device (100), comprising a melt extrusion module (102), a printing module (103), and a platform module (104). The melt extrusion module (102) comprises a processing chamber (121) consisting of a feed inlet (124) and a discharge outlet (125), as well as an extrusion means (122) and a heating means (123) disposed at the processing chamber; the melt extrusion module (102) is configured to receive an initial material from the feed inlet (124) of the processing chamber (121), and heat and extrude the initial material to convert the initial material into a molten body, which is extruded out of the discharge outlet (125) of the processing chamber (121). The printing module (103) is communicated with the discharge outlet (125) of the processing chamber (121) and is provided with a nozzle (131); the printing module (103) is configured to receive the molten body extruded from the discharge outlet (125) of the processing chamber (121) and guide the molten body to be extruded out of the nozzle (131).

Abstract: The present disclosure generally relates to an additive manufacturing system. The system can comprise a material supply module for melting and pressurizing a printing material; a micro-screw printing head comprising: a micro-screw comprising a threaded stem portion and a conical head portion, wherein the threaded stem portion is threaded throughout its length for volume measurement; a sleeve, and a nozzle, wherein a distal end of the nozzle comprises: a conical inner surface, and an outlet port for dispensing the print material, wherein the conical inner surface of the nozzle is configured to be in contact with the conical head portion of the micro-screw to stop dispensing the printing material at the nozzle when the micro-screw printing head is in a closed position; a driving module comprising: a rotation motor for driving a rotating motion of the micro-screw, and an actuator for driving a vertical motion of the micro-screw.

Abstract: The present disclosure relates generally to manufacturing pharmaceutical products using additive manufacturing technology.

Abstract: The disclosure provides an engineering bacterium for ferulic acid production, a preparation method of the bacterium and use thereof. The invention provides an engineering bacterium that can efficiently produce ferulic compounds by expressing a series of heterologous enzymes in a host cell through gene recombination technology. The expression system constructed by the invention has low metabolic background, strong heterologous expression ability and low cost. The system can synthesize the end product through relatively simple steps, and provide a new way for the industrial production of ferulic acid, intermediates or derivatives thereof.

Abstract: An electronic device to: present a Graphical User Interface (GUI) to a user, the GUI including a plurality of selectable elements and one or more parameter controls associated with each of the plurality of selectable elements, each of the plurality of selectable elements corresponding to a feature of a network access device; receive a user selection of at least one of the plurality of selectable elements; receive one or more parameter values associated with the at least one selectable element inputted by the user via the parameter controls; and generate a configuration file of the network access device based at least on the at least one selectable element selected by the user, and the one or more parameter values associated with the at least one selectable element inputted by the user, in response to an activation of a first interactive button on the GUI by the user.

Abstract: The present disclosure relates generally to manufacturing pharmaceutical products using additive manufacturing technology.

Abstract: A 3D printing device (100), comprising a melt extrusion module (102), a printing module (103), and a platform module (104). The melt extrusion module (102) comprises a processing chamber (121) consisting of a feed inlet (124) and a discharge outlet (125), as well as an extrusion means (122) and a heating means (123) disposed at the processing chamber; the melt extrusion module (102) is configured to receive an initial material from the feed inlet (124) of the processing chamber (121), and heat and extrude the initial material to convert the initial material into a molten body, which is extruded out of the discharge outlet (125) of the processing chamber (121). The printing module (103) is communicated with the discharge outlet (125) of the processing chamber (121) and is provided with a nozzle (131); the printing module (103) is configured to receive the molten body extruded from the discharge outlet (125) of the processing chamber (121) and guide the molten body to be extruded out of the nozzle (131).